A Clinical Study on the Treatment of Peripheral Nerve Injury Growth Factor of Mecobalamin Combined with Nerve

Objective: This research aims to explore the clinical curative effect for the treatment peripheral nerve injury growth factor of Mecobalamin combined with nerve. Methods: 150 cases of patients with peripheral nerve injury treated in the hospital in July were selected from 2011 to 2013. Those patients were randomly divided into three groups according to the types of injured nerve and the undergoing treatment order. 50 cases are for each group. Patients in group A were injected with 0.5 mg Mecobalamin by intravenous injection. It lasted for once a day, for 10 days. Later, 0.5 mg Mecobalamin was changed to be taken orally, three times a day, a course of treatment. And a course is 3 to 6 weeks. 50 patients in group B were injected with nerve growth factor for 30 micrograms by intramuscular injection, once a day, a course of treatment. And a course is 3 to 6 weeks. While in group C, 50 patients were treated with Mecobalamin (0.5 mg, intravenous injection, once a day) combined with nerve growth factor (30 mg, intramuscular injection, once a day). A course lasted 3 to 6 weeks. The purpose is to observe the therapeutic effect of two different drugs on patients with peripheral nerve injury. Results: The curative effect of Mecobalamin combined with nerve growth factors for the treatment of peripheral nerve injury in group C is more significant than the single drug treatment in group A and group B. Peripheral nerve injury after sensorimotor function rating evaluation of curative effect made by The British Medical Research Institute of Neurotrauma Society was applied in this research. The comparison of the results of 3 groups after treatment is showed as follows. As to the sensory recovery above level II, the curative effect in C group is generally better than in group A and group B, the approximate chi square test H = 13.6573, P = 0.0011. About motion recovery situation, there is a statistical significance in group A and group C which recovered V level X2 = 3.8431, P = 0.0499, while there is no obvious difference in group B (P > 0.05). Conclusion: Some certain curative effect is presented of Mecobalamin combined with nerve growth factor in the treatment of peripheral nerve injury, which has an important clinical significance. Therefore, it is worth taking into application.

Study on Disease Distribution and Test Results of Tuberculosis of Regional Control Project in Guangxi, China

The purpose of this study is to investigate the disease distribution of tuberculosis in national regional project. 960 patients were selected from national tuberculosis control program who took treatments in the Fourth People’s Hospital Clinical Laboratory in Nanning Guangxi from January to November in 2013. Then we observed all those patients’ disease distribution and analyzed all the lab test indexes. We analyzed the results according to gender and age distribution. From the age distribution, we found that the incidence was lower at the age of 40 or younger, while higher incidence occurred to patients over 40 years old. There is statistical significance comparing these two age groups. P is less than 0.001. Disease distribution: 731 patients were infected with TB;21 patients were co-infected with tuberculosis (TB) and HIV. 196 patients were co-infected with TB and fungal. 12 patients were co-infected with TB, HIV and fungal. From the laboratory testing, we know there were 87 patients whose liver function indexes were abnormal. There were 192 patients whose blood RT indexes were abnormal. The liver function and blood RT indexes of patients with co-infection were higher than those infected purely. There is statistical significance in comparison P < 0.05. The study indicates that patients with older age are more likely infected with tuberculosis. In addition, there are a high proportion of patients with co-infection among these patients in this study. Meanwhile, the liver functions and blood RT indexes of patients combining with infection are higher than those infected TB purely. Prompt clinical prevention and treatment should be under reasonable inspections. General analysis can enable us to investigate more effective treatment plan. Then the best treatment result will be obtained.

Investigation and Analysis on Pathogen Distribution of HIV/AIDS Patients with Opportunistic Infection

Objective: This study aims to understand the distribution of pathogenic bacteria in the region of HIV/AIDS patients with opportunistic infection. Methods: To count the number of the bacterial culture of HIV/AIDS patients in our hospital from October 2011 to December 2014, and observe the distribution of all kinds of pathogenic bacteria. Results: From the 4269 cases of HIV/AIDS patients’ bacteria, 5045 cases were cultured whose main flora distribution wasCandida albicans, 1759 cases. The second one was penicillium, 982 cases. The third one was mycobacteria, 557 cases. And then there are 213 cases ofCryptococcus neoformans, 212 cases of?Klebsiella pneumonia, 209 cases of?E. coli, 157 cases of coagulase-negative staphylococci, 112 cases of?Candida tropicalis, 90 cases of glabrata, 81 cases of?Staphylococcus aureus, 75 cases of?Pseudomonas aeruginosa, 60 cases of Salmonella, 48 cases of Acinetobacter and the distribution of the rest of cultured bacterial was less than 40 cases. Conclusion: There are many kinds of types of Pathogenic bacteria in HIV/AIDS patients with the opportunity to infectious. And the majorities are?Candida albicans,?Penicillium marneffei,?Penicillium,?Mycobacterium,?Cryptococcus neoformans?and so on. The infection sites are widely distributed;respiratory and circulatory are the main infected system. Improving the detection rate and reducing the contamination rate can truly reflect the distribution of pathogenic bacteria, and the distribution can guide the infection work in hospital. At the same time, it’s good to predict and prevent opportunistic infection. Thus, the patients can get immediate treatment.

Analysis on Immune Tolerance and Resistance Mechanism of <i>Cryptococcus albidus</i>of AIDS Patients with Opportunistic Cryptococci Infection

Objective: To explore more about the immune tolerance and drug resistance of white Cryptococci albidus in AIDS patients with opportunistic Cryptococcus infection. Methods: To analyze drug resistance of the samples of white Cryptococcus albidus extracted from opportunistic infection AIDS patients in the certain infection area from October 2011 to December 2014. Results: After analyzing two samples of Cryptococcus albidus from 885 cases with opportunistic infection, we found that one of the samples do resist to ten common antibiotics. They were fluconazole, flu-cytosine, fluconazole, caspofungin, amphotericin B, MI miconazole, terbinafine, ketoconazole and itraconazole. The other one was sensitive to voriconazole, but resistant to the rest of the drug. Two strains of bacteria were inoculated into the animals in vivo and their DNA was extracted to carry out the genotyping analysis. The results showed that different degrees of resistance gene amplification bands were found in the 10 kinds of antibiotics. Conclusion: Although there were few opportunistic infection Cryptococcus albidus in AIDS patients, it was easy to show its resistance to drugs. Therefore, great attention should be paid to it for the medical workers.